Logo

Stratagene Shares Up 5.9 Percent on New Dx Patent Award

Jul 11, 2005

NEW YORK, July 11 (GenomeWeb News) - Shares in Stratagene were up 5.9 percent, or $.51, at $9.14 in late-afternoon trading after the company said it won a US patent for its FullVelocity technology.

 

The patent, No. 6,893,819, is entitled "Methods for Detection of a Nucleic Acid by Sequential Amplification." According to Stratagene, it covers "novel methods for the detection of infectious agents, cancer and genetic traits."

 

It is the fifth patent the company has won for the FullVelocity technology.

 

The technology described in the patent "can enhance FullVelocity and Taq-based chemistries by offering increased multiplexing capabilities at a potentially lower cost," Stratagene president and CEO Joseph Sorge said in a statement.

Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.